Bisphosphonate therapy in fibrous dysplasia.
Fibrous dysplasia is proliferation of fibrous tissue within the bone marrow causing osteolytic lesions and pathologic fractures. Recently, second generation bisphosphonates have shown promise in the treatment of patients with fibrous dysplasia. In the current study, six patients with fibrous dysplasia were treated with either oral alone or oral and intravenous bisphosphonates. The participants were observed for changes in N-telopeptide, pain score, and radiographic changes. In the current study, the combination bisphosphonate therapy diminished pain, prevented fractures, lowered N-telopeptide values, and led to partial resolution of fibrous dysplasia lesions.
Lane
J M
JM
Weill Medical College of Cornell University, Hospital for Special Surgery, New York, NY 10021, USA.
Khan
S N
SN
O'Connor
W J
WJ
Nydick
M
M
Hommen
J P
JP
Schneider
R
R
Tomin
E
E
Brand
J
J
Curtin
J
J
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000652:urine; D001842:Bone and Bones / Q000187:drug effects; D003094:Collagen / Q000652:urine; D024042:Collagen Type I; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005357:Fibrous Dysplasia of Bone / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010012:Osteogenesis / Q000187:drug effects; D010014:Osteolysis / Q000517:prevention & control; D010147:Pain Measurement; D000077268:Pamidronate; D010455:Peptides / Q000652:urine; D011859:Radiography; D018709:Statistics, Nonparametric
D015415:Biomarkers; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D003094:Collagen; D000077268:Pamidronate; D019386:Alendronate